<DOC>
	<DOCNO>NCT01458912</DOCNO>
	<brief_summary>The aim study ass compare efficacy safety BI 54903 medium dos twice daily high dos daily ( even dose ) placebo 12-week treatment period asthmatic patient age 12 65 year inadequately control low dose inhale corticosteroid ( ICS ) therapy demonstrate decrease Forced Expiratory Volume one second ( FEV1 ) ( le 10 % , equal less 25 % ) Asthma Control Questionnaire ( ACQ ) -6 score less 1.5 time randomisation .</brief_summary>
	<brief_title>Study BI 54903 ( Inhaled Corticosteroid ) Administered Once Daily Twice Daily Via Respimat Inhaler Patients With Asthma Inadequately Controlled Low Dose Inhaled Corticosteroids</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>Inclusion criterion : Male female patient age least 12 65 year . All patient must history asthma diagnose physician least three month time enrolment trial accord 2009 Global Initiative Asthma ( GINA ) Guidelines . The initial diagnosis asthma must make age 40 year . All patient must maintenance treatment either mediumdose ICS plus Longacting beta agonist ( LABA ) highdose ICS without LABA , stable least six week prior Visit 1 ( see also Section 3.3.1 Appendix 10.3 ) . All patient must prebronchodilator FEV1 le 60 90 % predict normal ACQ6 mean score le 1.5 prescreening Visit 1 . All patient must improvement FEV1 le 12 % baseline absolute change least 200 mL within 1530 min administration 400 mcg salbutamol/albuterol Hydrofluoroalkane ( HFA ) Metered Dose Inhaler ( MDI ) . When reversibility achieve Visit 1 , option repeat reversibility test visit runin period . Variation absolute prebronchodilator FEV1 value Visit 2 compare Visit 1 must within plus/minus 20 % . Patients must neversmokers exsmokers smoke history less than10 packyears smoke cessation least one year prior screen . Patients must able use Respimat® inhaler MDI correctly Patients must able perform trialrelated procedure include technically acceptable pulmonary function test electronic PEF measurement , must able maintain record study period require protocol . To enter treatment period follow additional criterion meet ( randomisation visit ) : All patient must improvement FEV1 le 12 % baseline absolute change least 200 mL within 1530 min administration 400 mcg salbutamol/albuterol HFA MDI . When reversibility achieve Visit 1 , option repeat reversibility test visit runin period . During runin period ( clinic visit ) patient must symptomatic ( ACQ6 mean score equal great 1.5 ) show decrease morning prebronchodilator FEV1 le 10 % less equal 25 % prescreening baseline FEV1 Visit 2 . Exclusion criterion : Patients significant pulmonary disease asthma significant medical condition ( determine medical history , examination clinical investigation screen ) may , opinion investigator , result following : ( ) put patient risk participation trial ( ii ) influence result trial ( iii ) cause concern regard patient 's ability participate trial . Patients clinically relevant , abnormal screen haematology and/or blood chemistry finding , abnormality indicate significant disease define exclusion criterion . 1 . Patients history upper low respiratory tract infection ( URTI/LRTI ) past four week prior prescreening Visit 1 , prescreening runin period . Patients exacerbation underlie asthma eight week prior prescreening Visit 1 . Patients active allergic rhinitis require treatment systemic corticosteroid . Any following criterion meet prescreening / runin period ( Visits 1 6 ) : clinic prebronchodilator FEV1 % predict less 40 % , 12 puff rescue salbutamol/albuterol HFA MDI per day &gt; 2 consecutive day , exacerbation asthma . Patients history pneumonectomy plan undergo thoracotomy reason . Patients currently pulmonary rehabilitation program complete pulmonary rehabilitation program six week prior first screen visit 1 . Patients two hospitalization asthma within previous 12 month . Patients recent history myocardial infarction last twelve month know coronary heart disease require treatment Patients history hospitalisation due heart failure past twelve month Patients myocarditis unstable lifethreatening cardiac arrhythmia cardiac arrhythmia require intervention change drug therapy within past year Patients significant alcohol drug abuse opinion investigator within past two year Patients rheumatoid arthritis systemic disease require immune system modulate treatment Patients suffer history glaucoma , increase intraocular pressure , and/or cataract Pregnant nursing woman Women childbearing potential use highly effective method birth control . Patients treated antiIgEantibodies ( e.g . omalizumab Xolair® ) immune system modulate antibody TNFalpha blocker within six month prior Visit 1 . Patients treat follow drug past four week prior Visit 1 foreseen need study : Nonselective ßblockers ( topical cardioselective betablocker eye medication nonnarrow angle glaucoma allow ) , Oral systemic corticosteroid , Oral betaagonists , Changes allergen desensitisation therapy last 6 month , Immune system modulate agent methotrexate cyclosporine , Inhibitors cytochrome P450 3A4 antifungal ( e.g . ketoconazole , itraconazole ) , antibiotic ( e.g . erythromycin ) antiretroviral drug . Patients treat leukotriene modifier , cromones theophylline within two week prior Visit 1 . Patients treat tiotropium within 3 week prior Visit 1 .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2011</verification_date>
</DOC>